Biotech Tracker
MilestoneH1 2027a window, not a day

Nuvaxovid manufacturing tech transfer to Sanofi completion ($75M milestone)

Nuvaxovid manufacturing tech transfer to Sanofi completion ($75M milestone), expected in the first half of 2027 (no exact date yet). A company milestone for Novavax (Nuvaxovid for COVID-19): a step in the program rather than a decision or a data readout.

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary

DetailsCompany milestone
Company
Novavax, Inc. NVAX
Drug
Nuvaxovid
For
COVID-19
Stage
Commercial / partnership
When
H1 2027 · the company gave a window, not a day; the calendar never invents one
Source note
Novavax Aug 6, 2026 Q2 release: manufacturing technology transfer to Sanofi expected to complete mid-2027, triggering a $75M milestone. 'mid-2027' mapped to 2027-H1 per convention (could slip into early H2).
Checked
Checked by a person when it was added
Check the sourcesdon’t take our word for it
Novavax, Inc.
2 upcoming · 2 past catalysts
More from NVAX
MilestoneNVAXNovavax2027

Novavax C. difficile vaccine clinical entry as early as 2027, expected during 2027 (no exact date yet). A company milestone for Novavax (C. difficile vaccine candidate for Clostridioides difficile infection): a step in the program rather than a decision or a data readout.

More details
Entry
Novavax C. difficile vaccine clinical entry as early as 2027 · Company milestone
Drug
C. difficile vaccine candidate
For
Clostridioides difficile infection
Stage
Preclinical / pre-IND
When
2027 · the company gave a window, not a day
Source note
Q2 2026 release: candidate advanced into pre-IND interactions with FDA and GMP manufacturing initiated, supporting potential clinical entry as early as 2027 (hedged 'as early as').
Checked
Checked by a person when it was added
Verify it

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page